We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 13, 2020

Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. Clin. Oncol 2020 May 27;[EPub Ahead of Print], P Ghia, A Pluta, M Wach, D Lysak, T Kozak, M Simkovic, P Kaplan, I Kraychok, A Illes, J de la Serna, S Dolan, P Campbell, G Musuraca, A Jacob, E Avery, JH Lee, W Liang, P Patel, C Quah, W Jurczak

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading